Literature DB >> 7467874

[Liability for hepatitis after blood transfusion (author's transl)].

H Fiedler, B Hackethal.   

Abstract

1) Only a very limited amount of all cases of so-called "post-transfusion-hepatitis" (pth) is really due to infectivity of the transfused blood. Regardless of the mostly unknown true source of the infection, the occurrence of "pth" for itself does not qualify the recipient and/or his illness-insurance company for a legitimate action for damages against the blood bank under current West Germany Federal Law. 2) All West German blood banks are obliged by Federal Law to insure themselves against strictly defined damage claims. Their damage-insurance companies are not entitled to pay compensations to the illness-insurance companies of any victim of "pth" without meticulous investigation of the exact circumstances if expenses exceeding the legally defined limitations are included in the premium of damage-insurance charged to the blood banks. 3)Since nearly all inhabitants of West Germany are legally or voluntarily insured against illness, compensations paid by damage-insurance companies to illness-insurance companies are no appropriate means for any cost containment of the latter: The blood banks have no other choice than to calculate the additional premium costs into the costs of the blood units to be debitted to the illness-insurance companies.

Entities:  

Mesh:

Year:  1980        PMID: 7467874     DOI: 10.1007/bf00200974

Source DB:  PubMed          Journal:  Z Rechtsmed        ISSN: 0044-3433


  3 in total

1.  [Hepatitis following blood transfusions].

Authors:  H Busch; D Roos; W Creutzfeldt
Journal:  Dtsch Med Wochenschr       Date:  1971-10-22       Impact factor: 0.628

2.  [Hospital-acquired hepatitis type B. Report of 6 cases (author's transl)].

Authors:  M Brodersen; W Folger
Journal:  Med Klin       Date:  1976-04-09

3.  [Epidemiology and prognosis of non-A, non-B hepatitis (author's transl)].

Authors:  R Müller; H Willers; K W Knocke; S Sipos; W Höpken
Journal:  Dtsch Med Wochenschr       Date:  1979-10-19       Impact factor: 0.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.